David Olson

Company: Delix Therapeutics

Job title: Chief Innovation Officer

Seminars:

Bolstering the Development of Novel Neuroplastogens & Deciphering Their True Classification 9:45 am

Outlining the research paradigms that can be leveraged during discovery to prioritize compounds that will most likely have non-hallucinogenic effects in man Utilizing translationally relevant assays to decipher the complex activity profile of novel neuroplastogens before moving into humans Clarifying the classification of neuroplastogens: what key testing criteria should be used to benchmark novel plastogens?Read more

day: Day Two AM